Why two different scores are used together

When a consultant mentions two separate scores after a ChondroFiller injection, the natural question is what each one is actually measuring — and why neither is sufficient on its own.

The answer lies in what each instrument sees. The IKDC score reflects how the knee feels and performs in daily life: climbing stairs, returning to sport, walking without pain. The MOCART score, applied by a radiologist to an MRI scan, shows how completely the collagen scaffold has filled the defect and how well the repair tissue is integrating with the surrounding cartilage.

The two do not always move in step. A patient may feel considerably better — enough to notice in everyday activity — before the MRI shows fully mature repair tissue. Equally, good structural fill on imaging does not automatically guarantee symptom relief. Tracking both together gives the treating clinician a clearer picture of recovery: one score captures the patient's experience of their knee; the other captures the cartilage's structural progress.

The IKDC score — what it measures and what the numbers mean

The IKDC questionnaire is completed by the patient before and after treatment — no imaging, no clinical examination, just answers to 18 questions about how the knee feels and what it will and won't allow. Seven questions cover symptoms such as pain, swelling, and stiffness; nine ask about daily activities like climbing stairs, crouching, or walking on uneven ground; one addresses sports participation. Every answer feeds into a single 0–100 total, where 100 means no limitation whatsoever.

The number that makes the score clinically useful is 16.7 — the minimal clinically important difference, or MCID. This is the threshold that tells us whether a change is real in daily life, not just statistical noise. A shift of five or ten points may appear on paper but fall below the level a patient would notice. Only once a change exceeds 16.7 points can it reliably be called a meaningful improvement.

A score of around 80 gives a practical sense of what that improvement looks like: comfortable recreational activity, no significant restriction on daily tasks, and a return to light sport for most patients. It is not perfect function, but it sits well above the moderate-to-severe limitation that characterises an untreated focal cartilage defect.

In ChondroFiller™ cohorts, patients typically begin with a baseline IKDC of roughly 48 — a score consistent with persistent pain and meaningful activity restriction. That starting point matters because it frames the scale of the recovery journey ahead and explains why a 30-point gain represents a substantial shift in lived experience rather than a marginal adjustment.

The MOCART score — what MRI reveals about cartilage repair

MRI gives a structural view that X-ray cannot: the depth, texture, and margins of cartilage repair tissue. The MOCART score (Magnetic Resonance Observation of Cartilage Repair Tissue, defined by Marlovits et al.) translates that visual information into a 0–100 number by assessing four specific domains.

The first is completeness of defect fill — how much of the original lesion the repair tissue now occupies. The second is peripheral integration — whether the new tissue blends smoothly into the surrounding native cartilage or leaves a visible gap. The third, surface congruity, checks whether the repair tissue sits flush with the adjacent joint surface rather than protruding or receding. The fourth domain is signal intensity: healthy hyaline cartilage has a characteristic appearance on MRI; repair tissue that is maturing towards hyaline-like quality increasingly mirrors that pattern, while fibrocartilage — a less durable alternative — looks distinctly different. Signal intensity is, in practice, a measure of how closely the repair tissue resembles healthy cartilage in texture, not just in volume.

A score above 80 indicates more than 80% defect fill with good peripheral integration. In ChondroFiller™ cohorts, one-year scores typically sit between 70 and 87 — a range that reflects genuine structural progress at the twelve-month mark, not a shortfall from some theoretical ideal.

The critical caveat is timing. MOCART is a maturation indicator: the acellular scaffold gradually resorbs as repair tissue forms, and scores continue to evolve across months. A first post-injection MRI at three or six months will usually look less complete than one taken at twelve months — expected behaviour rather than a sign that treatment has not worked.

ChondroFiller's actual outcome data — the numbers in context

Across four prospective knee cohorts synthesised in the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025), the mean IKDC improvement at twelve months is approximately 30 points. Set against the 16.7-point MCID established in s2, that gain is nearly double the threshold at which a patient notices a real difference in daily life — not a marginal shift, but a substantive change in what the knee will and will not allow.

Patients begin at a baseline IKDC of roughly 48 and reach approximately 80.1 by 36 months. That trajectory describes a move from persistent, activity-limiting pain to the level of function associated with comfortable recreational activity and manageable daily tasks — a clinically meaningful destination rather than a statistical average.

The timing of that gain is arguably as important as its size. Most of the functional improvement consolidates within the first twelve months; scores then plateau rather than continuing to climb. For patients planning around their recovery, this means the bulk of the work — by the joint's own biological timetable — is done within a year.

On imaging, one-year MOCART scores in ChondroFiller™ cohorts cluster between 70 and 87. As the domains described in the preceding section make clear, scores in this range reflect adequate defect fill, good peripheral integration with surrounding native cartilage, and maturing tissue signal — structural findings that correspond to the functional gains the IKDC captures.

Two independent study lines corroborate these figures. A 2016 prospective multi-centre trial and Simeonov's 2024 cohort (17 patients, mean age 31) both recorded statistically significant IKDC and Lysholm improvements at 3, 6, and 12 months (p<0.05). Across independent cohorts followed to five years, approximately 70–85% of patients report sustained pain reduction and functional recovery.

How scores evolve during recovery — what to expect at each stage

Recovery from a ChondroFiller™ injection does not follow a uniform curve, and the timing differences between functional and structural improvement have practical consequences worth understanding before the procedure.

In the early weeks, the collagen gel is mechanically immature — it has filled the defect but host progenitor cells have not yet migrated in sufficient numbers to begin forming durable repair tissue. This is the rationale for strict weight-bearing restrictions during the maturation window: compression on an unsupported scaffold risks displacing or disrupting it before acellular matrix-induced chondrogenesis is under way. The restriction is not precautionary convention but a direct consequence of where the biology is at that stage.

Functional improvement, as captured by the IKDC, typically becomes measurable around three months and is statistically significant by six. As noted in the outcome data in the preceding section, the plateau — around 80 — is usually established by twelve months. Patients often feel the bulk of their recovery within that first year.

Structural consolidation, by contrast, continues beyond that point. One-year MOCART scores of 70–87 represent meaningful progress, but repair tissue can still be maturing at 18 or 24 months as the collagen matrix degrades and host cartilage cells consolidate. A brief callback to s3 suffices here: MOCART is a maturation indicator, not a final verdict.

The practical implication: a good IKDC score at twelve months is not a signal that later imaging can be skipped. The functional and structural arcs diverge in pace, and the review schedule should account for both.

Putting the evidence in perspective — and finding out if you are a candidate

Four independent prospective cohorts deliver a consistent signal — but consistency is not the same as certainty from a large randomised trial. The studies synthesised in CER v09 (April 2025) come from smaller populations, and long-term head-to-head data against microfracture or matrix-induced autologous chondrocyte implantation (MACI) remain limited. That is an acknowledged gap in the literature rather than a reason to discount the findings, but it is a relevant consideration when setting this option alongside procedures with deeper trial records.

The treatment is designed for a specific structural situation: focal, contained Grade III or IV cartilage damage with an intact subchondral plate and reasonably healthy surrounding tissue. Simeonov's 2024 cohort — seventeen patients, mean age 31, all presenting with focal defects — illustrates the kind of profile the procedure is built around. Where damage is diffuse, or the joint has progressed to generalised bone-on-bone wear, ChondroFiller™ is unlikely to be appropriate; the scaffold-directed repair it relies on depends on a viable biological environment that end-stage osteoarthritis does not provide.

In the UK, the treatment is self-funded; it is not NHS-commissioned and is not covered by Bupa or AXA — a practical consideration worth clarifying before any assessment.

Whether ChondroFiller™ suits any given patient turns on defect geometry, overall joint condition, and clinical history — none of which can be resolved without imaging and specialist review. Patients based in or around London can arrange that assessment via londoncartilage.com.